Recruiting now—Ages 40 Years and up

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Sponsor: Adela, Inc · NCT05366881 on ClinicalTrials.gov ↗

Conditions studied

Brain CancerBreast CancerBladder CancerCervical CancerColorectal CancerEndometrial CancerEsophageal CancerStomach CancerHead and Neck CancerHepatobiliary CancerLeukemiaLung CancerLymphomaMultiple MyelomaOvarian CancerPancreatic CancerProstate CancerRenal CancerSarcomaThyroid Cancer

Where it's running17 sites

City of Hope
Duarte, California 91010
Recruiting now
- Xiao-Yu Xia(contact)626-218-0630 [email protected]
- Gregory Idos, MD(principal investigator)
Miami Cancer Institute
Miami, Florida 33176
Recruiting now
- Belkys Salinas(contact)[email protected]
- Manmeet Ahluwalia, MD(principal investigator)
North Georgia Health System
Gainesville, Georgia 306501
Recruiting now
- Trena Davis(contact)[email protected]
- Charles Nash, MD(principal investigator)
Baptist Floyd
New Albany, Indiana 47150
Recruiting now
- Tasha Dodson(contact)[email protected]
- Amitoj Gill, MD(principal investigator)
Baptist Corbin
Corbin, Kentucky 40701
Recruiting now
- Janie Platt(contact)[email protected]
- Abigail Byrnes, MD(principal investigator)
Baptist Hardin
Elizabethtown, Kentucky 42701
Recruiting now
- Amy Steward(contact)[email protected]
- Christopher Burkeen, MD(principal investigator)
Baptist Lexington
Lexington, Kentucky 40503
Recruiting now
- Janie Platt(contact)[email protected]
- Arvinda Padmanabhan, MD(principal investigator)
Baptist Paducah
Paducah, Kentucky 42003
Withdrawn
Allina Health Cancer Institute
Minneapolis, Minnesota 55407
Recruiting now
- Jonathon Alexander(contact)612-863-8625 [email protected]
- Jennie Schletty(contact)612-863-8625 [email protected]
- Joleen Hubbard, MD(principal investigator)
Mayo Clinic
Rochester, Minnesota 55902
Recruiting now
- Angela R Emanuel(contact)[email protected]
- Lisa A Boardman, MD(principal investigator)
Cleveland Clinic
Cleveland, Ohio 44195
Recruiting now
- Mofetoluwa Oluwasanmi(contact)216-444-0843 [email protected]
- Peter Mazzone, MD, MPH(principal investigator)
Oregon Health Sciences University
Portland, Oregon 97201
Recruiting now
- Diana Potts(contact)[email protected]
- Nima Nabavizadeh, MD(principal investigator)
Medical University of South Carolina
Charleston, South Carolina 29425
Recruiting now
- Michael Balassone(contact)843-792-6696 [email protected]
- Andrew M Chen(contact)[email protected]
- Gerard Silvestri, MD(principal investigator)
McLeod Health
Florence, South Carolina 29502
Recruiting now
- Betsy Harris(contact)[email protected]
- Virginia Clyburn-Ipock, MD(principal investigator)
Baptist (BHMCC)
Memphis, Tennessee 38120
Recruiting now
- Tracy Stewart(contact)[email protected]
- Philip Lammers, MD(principal investigator)
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee 37203
Recruiting now
- Anna Dumont(contact)[email protected]
- Brian Rini, MD(principal investigator)
Elligo Health Research, Inc.
Austin, Texas 78704
Recruiting now
- Cynthia Currasco(contact)[email protected]
- Faith Holmes, MD(principal investigator)

See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Case Inclusion Criteria:

* Newly diagnosed (within 120 days) with cancer or a recurrence of a cancer diagnosed \>5 years ago of one of the following subtypes: Invasive Brain, Breast, Bladder, Cervical, Colorectal, Endometrial, Esophageal, Gastric, Head and Neck, Hepatobiliary, Lung, Ovarian, Pancreatic, Prostate, Renal, Sarcoma, Thyroid; Leukemia, Lymphoma, Multiple Myeloma
* Able and willing to provide informed consent
* ≥40 years of age

Case Exclusion Criteria:

* Currently receiving any treatment for cancer
* Currently taking any demethylating agents/DNA hypomethylating agents
* Simultaneously diagnosed with two or more invasive cancers
* Diagnosed with any invasive or non-invasive cancer in addition to the index cancer in the last 5 years
* Currently diagnosed with any chronic hematopoietic cancer (e.g. chronic CLL) in addition to the index cancer
* Currently diagnosed with any myelodysplastic syndromes and/or precursor hematologic conditions (e.g. MGUS) in addition to the index cancer
* Women who are known to be pregnant (self-reported)

Control Inclusion Criteria

* Not diagnosed with any cancer in the last 5 years (non-invasive cancer is allowed)
* Able and willing to provide informed consent
* ≥40 years of age

Control Exclusion Criteria

* Currently receiving any treatment for cancer
* Currently taking any demethylating agents/DNA hypomethylating agents
* Women who are known to be pregnant (self-reported)

Updated 2026-01-20 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.